Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.68 |
| ▸ | CDK2 | P24941 | 11/20 | 0.67 |
| ▸ | CDC7 | O00311 | 10/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.67 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.49 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30459871 | 1.00 | RPS6KA5 (0.68) | RPS6KA5CDK2CDC7ROCK1MKNK1 | |
| SCHEMBL19100953 | 0.82 | CDC7 (0.68) | RPS6KA5CDK2CDC7MAPT | |
| SCHEMBL19337066 | 0.81 | RPS6KA5 (0.61) | RPS6KA5CDK2CDC7ROCK1MAP3K14 | |
| SCHEMBL19100965 | 0.81 | RPS6KA5 (1.00) | RPS6KA5CDK2CDC7ROCK1MAP3K14 | |
| SCHEMBL19100396 | 0.81 | CDC7 (0.68) | RPS6KA5CDK2CDC7ROCK1MKNK2 | |
| SCHEMBL9377410 | 0.80 | CDC7 (1.00) | CDK2CDC7ROCK1MAP3K14 | |
| SCHEMBL19533417 | 0.80 | CDK2 (0.67) | RPS6KA5CDK2CDC7ROCK1MKNK1 | |
| SCHEMBL30753972 | 0.80 | CDC7 (1.00) | CDK2CDC7ROCK1MAP3K14 | |
| SCHEMBL17888130 | 0.79 | CDC7 (0.68) | RPS6KA5CDK2CDC7ROCK1MAP3K14 | |
| SCHEMBL28664988 | 0.79 | CDC7 (0.56) | RPS6KA5CDK2CDC7ROCK1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331037-B2 | Pyrimidines as EGFR-inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230115945-A1 | AMINOPYRIMIDINE COMPOUNDS | TYRA BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4085055-A1 | AMINOPYRIMIDINE COMPOUNDS | Tyra Biosciences, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | BEBETTER MED INC. (CN) | 2022-03-08 | — | — | US | disclosed |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | InventisBio Co., Ltd. (CN) | 2021-12-21 | — | — | US | disclosed |
| CN-113563332-A | Novel pyrimidines as EGFR inhibitors and methods of treating disorders | 达纳－法伯癌症研究所公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2016105525-A2 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| CN-101568530-A | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors | NOVARTIS AG (CH) | 2009-10-28 | — | — | CN | disclosed |
| US-7282504-B2 | Kinase inhibitors | AMGEN INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282504-B2 | Kinase inhibitors | AMGEN INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282504-B2 | Kinase inhibitors | AMGEN INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050203114-A1 | Kinase inhibitors | AMGEN INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20030199534-A1 | Di-substituted pyrimidine compound for treating or modulating disease in which phosphoryl transferase, including kinases may be involved | AMGEN INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030004174-A9 | Kinase inhibitors | AMGEN INC. | 2003-01-02 | — | — | US | disclosed |
| US-20020052386-A1 | Kinase inhibitors | ARMISTEAD DAVID M (US) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203114-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K6 | RPS6KA5 352/4885CDK2 48/4885CDC7 111/4885 |
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | RPS6KA5 517/4885CDK2 66/4885CDC7 635/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | RPS6KA5 1451/4885CDK2 132/4885CDC7 2444/4885 |
| US-20030199534-A1 | Di-substituted pyrimidine compound for treating or modulating disease in which phosphoryl transferase, including kinases may be involved | DTYMK, PHKG1, TK1 | RPS6KA5 443/4885CDK2 31/4885CDC7 66/4885 |
| US-20030004174-A9 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K6 | RPS6KA5 352/4885CDK2 48/4885CDC7 111/4885 |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | EGFR, ERBB2, KRAS | RPS6KA5 559/4885CDK2 803/4885CDC7 2976/4885 |
| US-11203589-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, TP53 | RPS6KA5 1335/4885CDK2 450/4885CDC7 2184/4885 |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | RPS6KA5 498/4885CDK2 61/4885CDC7 646/4885 |
| US-20230115945-A1 | AMINOPYRIMIDINE COMPOUNDS | FGFR2, FGFR1, FGFR4 | RPS6KA5 178/4885CDK2 24/4885CDC7 624/4885 |
| US-20020052386-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K6 | RPS6KA5 352/4885CDK2 48/4885CDC7 111/4885 |
| US-12331037-B2 | Pyrimidines as EGFR-inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | RPS6KA5 656/4885CDK2 67/4885CDC7 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.